Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$25.27
-2.5%		$31.36
$18.84
▼
$39.61
$1.80BN/A674,203 shs1.13 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$12.95
+14.2%		$8.56
$5.37
▼
$18.22
$763.64M1.793.41 million shs4.51 million shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.44
+3.2%		$7.18
$2.55
▼
$9.42
$1.87B0.542.73 million shs2.30 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$159.78
+5.1%		$144.32
$23.30
▼
$219.71
$9.53B2.193.12 million shs3.54 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
-2.47%-26.46%-12.74%-11.08%+2,526,999,900.00%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+13.85%+4.95%+91.12%+42.31%-19.52%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+3.19%-5.82%+7.05%+22.17%+123.42%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+5.08%-15.31%+27.29%+76.28%+387.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$25.27
-2.5%		$31.36
$18.84
▼
$39.61
$1.80BN/A674,203 shs1.13 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$12.95
+14.2%		$8.56
$5.37
▼
$18.22
$763.64M1.793.41 million shs4.51 million shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.44
+3.2%		$7.18
$2.55
▼
$9.42
$1.87B0.542.73 million shs2.30 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$159.78
+5.1%		$144.32
$23.30
▼
$219.71
$9.53B2.193.12 million shs3.54 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
-2.47%-26.46%-12.74%-11.08%+2,526,999,900.00%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+13.85%+4.95%+91.12%+42.31%-19.52%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+3.19%-5.82%+7.05%+22.17%+123.42%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+5.08%-15.31%+27.29%+76.28%+387.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALMR
Alamar Biosciences
2.57
Moderate Buy$31.8025.84% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$6.33-51.09% Downside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.60
Moderate Buy$7.38-0.87% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.46
Hold$128.17-19.79% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, ALMR, and MRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
ALMR
Alamar Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
10/8/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$150.00
10/7/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$112.00 ➝ $215.00
10/5/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$9.00
10/5/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/1/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$107.00 ➝ $212.00
9/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$160.00 ➝ $190.00
9/21/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
BWS Financial logo
BWS Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$45.00
9/17/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$120.00 ➝ $160.00
9/9/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$2.50 ➝ $8.00
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALMR
Alamar Biosciences
$74.21M23.63N/AN/AN/A∞
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M5.13N/AN/A$8.74 per share1.48
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$185.74M10.40$0.43 per share17.22$1.46 per share5.10
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M26.61N/AN/A$7.84 per share20.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALMR
Alamar Biosciences
-$29.82M-$1.96N/AN/AN/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.52N/AN/AN/A-37.07%-15.70%-8.17%11/5/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$2.22N/AN/AN/A-31.66%-28.64%-19.94%11/13/2026 (Estimated)

Latest DNA, TWST, ALMR, and MRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.58N/AN/AN/A$21.57 millionN/A
11/5/2026Q3 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.0563N/AN/AN/A$43.56 millionN/A
8/11/2026Q2 2026
ALMR
Alamar Biosciences
-$0.36-$0.22+$0.14-$0.22N/A$29.43 million
8/6/2026Q2 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.0435-$0.02+$0.0235-$0.08$48.67 million$51.44 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.5063-$0.56-$0.0538-$0.56$114.55 million$118.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALMR
Alamar Biosciences
0.03
11.85
10.23
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.49
4.05
2.98
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.67
2.38

Institutional Ownership

CompanyInstitutional Ownership
ALMR
Alamar Biosciences
N/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
ALMR
Alamar Biosciences
N/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.49%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALMR
Alamar Biosciences
22269.39 millionN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
48567.34 million58.80 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
415259.67 million253.21 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
97962.71 million60.78 millionOptionable

Recent News About These Companies

Appearing as a "biotech company that synthesizes DNA," it has actually solidified its position as the "data infrastructure" for the era of AI-driven drug discovery ...
 |  note.comN
Twist Bioscience (NASDAQ:TWST) Stock Price Up 8.6% - Here's What Happened
October 9 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-twist-bioscience-nasdaq-twst-stock-price-up-86-heres-what-happened-2026-10-09/
Twist Bioscience (NASDAQ:TWST) Stock: Insider Emily Leproust Sells 4,548 Shares
October 9 at 4:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102780
Twist Bioscience: Valuation Stretched As AI Drug Discovery Hype Outpaces Reality
October 8 at 8:25 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4952717-twist-bioscience-stock-valuation-stretched-ai-drug-discovery-hype-outpaces-reality
Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $919,378.20 in Stock
October 8 at 6:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-twst-insider-buying-and-selling-2026-10-08/
Twist Bioscience stock fell 6.78 percent while its CEO sold shares
October 8 at 1:28 AM  |  ad-hoc-news.deA
Twist Bioscience slides as insider sale filings and partnership skepticism pressure sentiment
October 7 at 5:31 PM  |  quiverquant.comQ
Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 4,548 Shares of Company Stock
October 7 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-twist-bioscience-nasdaq-twst-ceo-emily-leproust-sells-4548-shares-of-company-stock-2026-10-07/
Twist Bioscience (NASDAQ:TWST) Shares Gap Down - Should You Sell?
October 7 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-twist-bioscience-nasdaq-twst-shares-gap-down-should-you-sell-2026-10-07/
Twist Bioscience (NASDAQ:TWST) Stock: Insider Robert Werner Sells 1,482 Shares
October 7 at 4:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095495
Twist Bioscience (NASDAQ:TWST) Stock: Insider Emily Leproust Sells 45,736 Shares
October 7 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095199
Twist Bioscience (NASDAQ:TWST) Stock: Insider Dennis Cho Sells 9,514 Shares
October 7 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095191
8,175 Twist Bioscience Corporation $TWST Shares Sold by Moody National Bank Trust Division
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-8175-twist-bioscience-corporation-twst-shares-sold-by-moody-national-bank-trust-division-2026-10-06/
Twist Bioscience stock gained 8.66 percent after Lilly deal on October 5, 2026
October 6, 2026  |  ad-hoc-news.deA
Twist Bioscience (NASDAQ:TWST) Stock Price Down 9.7% After Insider Selling
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092210
Twist Bioscience (NASDAQ:TWST) Stock Falls 9.7% Following Insider Selling
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-twist-bioscience-nasdaq-twst-stock-falls-97-following-insider-selling-2026-10-06/
Twist Bioscience (NASDAQ:TWST) Stock: Insider Emily Leproust Sells 655 Shares
October 6, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-twst-insider-buying-and-selling-2026-10-06/
Twist Bioscience (NASDAQ:TWST) CEO Sells 655 Shares of Company Stock
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-twist-bioscience-nasdaq-twst-ceo-sells-655-shares-of-company-stock-2026-10-05/
Twist Bioscience (NASDAQ:TWST) CAO Sells 1,482 Shares of Company Stock
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-twist-bioscience-nasdaq-twst-cao-sells-1482-shares-of-company-stock-2026-10-05/
Twist Bioscience (NASDAQ:TWST) Stock: Insider Adam Laponis Sells 8,057 Shares
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-twist-bioscience-nasdaq-twst-stock-insider-adam-laponis-sells-8057-shares-2026-10-05/
Twist Bioscience (NASDAQ:TWST) Insider Sells 9,514 Shares of Company Stock
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-twist-bioscience-nasdaq-twst-insider-sells-9514-shares-of-company-stock-2026-10-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alamar Biosciences NASDAQ:ALMR

$25.27 -0.64 (-2.47%)
As of 10/9/2026 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$12.95 +1.61 (+14.20%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$13.02 +0.07 (+0.54%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$7.44 +0.23 (+3.19%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.45 +0.01 (+0.13%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$159.78 +7.73 (+5.08%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$162.14 +2.36 (+1.48%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas